To provide a method for identifying a parameter indicative for susceptibility to 5-fluoro-uracil (5-FU) and/or a 5-FU analogue in all potential parameters suggested in the prior art, and for determining under what conditions the parameter provides the highest possible specificity.
The method for determining whether a patient suffering from cancer is susceptible to a treatment with the 5-FU and/or the 5-FU analogue comprises (a) determination of tymidine phosphorylase (TP) mRA expression in a clinical sample, (b) determination of diphydropyrimidine dehydrogenase (DPD) mRNA expression in the clinical sample, (c) determination of the ratio of the value obtained in step (a) to the value obtained in step (b), and (d) whether the ratio obtained in step (c) exceeds a predetermined cut off value.
KRAUSE FRIEDMANN
POIGNEE MANUELA
WALTER THOMAS
PORSTMANN BAERBEL
WERNER MARTIN
LASSMANN SILKE
Next Patent: SUCTION MASSAGE APPARATUS